RADX: radiopharmtheranostics.com P/S Multiple
Radiopharm Theranostics (RADX) benefits from a patent model where platform licensing ensures high margins alongside stable costs. This P/S chart illustrates the asset's market valuation, while the 5.00 metric confirms the current level. Stringent nuclear regulations and complex logistics create a high barrier to entry. Since the company is currently in the clinical trial stage, market pricing is not yet applied.
Metric breakdowns and analytics for Radiopharm Theranostics (RADX)
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Debt to Capital Radiopharm Theranostics|RADX - Long-Term Debt to Equity|Current Liabilities to Equity radiopharmtheranostics.com|RADX - Company Aggregate Debts|Debt to Net Assets Ratio Radiopharm Theranostics|RADX - Company Long-Term Debts|Company Short-Term Debts Radiopharm Theranostics|Intermediate Coverage Ratio radiopharmtheranostics.com
- net income and valuation multiples indicators:
RADX - Company Net Income|Future Profit Radiopharm Theranostics|RADX - Price to Earnings Ratio|Future Price to Earnings Multiple Radiopharm Theranostics Ltd|RADX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Radiopharm Theranostics|RADX - Operating profit EBITDA|Earnings per share for the trailing year Radiopharm Theranostics|RADX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months radiopharmtheranostics.com|RADX - Earnings per share growth in current year|Expected earnings per share trend next year Radiopharm Theranostics
- issuer revenue and sales details:
General company analysis:Radiopharm Theranostics Ltd, RADX
Radiopharm Theranostics (RADX) focuses on a narrow segment of radiopharmaceuticals, which makes the company dependent on the success of clinical trials. The P/S ratio relates market capitalization to annual revenue, measuring the cost of each unit of sales. Investors use this balance to identify asset overvaluation in the absence of real commercial income. The risk of a sharp decline in quotes is clearly reflected by the price/sales multiple level.
Competing companies
ONC (beigene.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|Ascentage - P/S Multiple|CGON (CG Oncology Therapeutics) - Market Cap to Revenue Ratio|URGN: P/S Multiple|BCAX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Personalis|Price to Sales Erasca Inc ERAS|Price-to-Revenue Ratio Delcath (DCTH)|YMAB: Price-to-Sales Ratio|P/S Multiple AURA (Aura Biosciences, Inc.)|Market Capitalization-to-Revenue Ratio CADL|Accuray - P/S Multiple|SLS - P/S Multiple|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Citius Oncology Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TuHURA Biosciences Inc.|Market Cap to Revenue protaratx.com (TARA)|Market Cap to Revenue FATE (Fate Therapeutics)|WHWK (aadibio.com) - Market Capitalization-to-Revenue Ratio|TScan Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume CSBR (Champions Oncology Inc)|XBiotech USA - P/S Multiple|Market Capitalization-to-Revenue Ratio CVM (CEL-SCI Corporation)|OSTX: P/S Multiple|Price to Sales Artiva Biotherapeutics (ARTV)|Price-to-Revenue Ratio Adlai Nortye Ltd|VERU: Market Capitalization-to-Revenue Ratio|P/S Multiple TPST|P/S Multiple xiliotx.com (XLO)|Price-to-Revenue Ratio Renovaro RENB|MURA: Market Cap to Revenue Ratio|KAPA - Price-to-Revenue Ratio|Price to Sales OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Price-to-Revenue Ratio|CRIS - Price-to-Revenue Coefficient|Market Cap to Revenue APLM|THAR (Tharimmune Inc) - Market Cap to Sales Volume|P/S Multiple ADVB|Price-to-Revenue Coefficient Genprex Inc|P/S Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Salarius Pharmaceuticals Inc SLRX|Purple Biotech Corp (PPBT) - Price-to-Revenue Ratio|American Oncology Network, Inc. - Market Capitalization-to-Revenue Ratio|BGNE (BeiGene, Ltd.) - P/S Multiple|P/S Multiple checkpointtx.com|P/S Multiple ELEV|icadmed.com - Market Cap to Revenue Ratio|Ikena Oncology - Market Cap to Revenue|NTBL: Market Cap to Revenue Ratio|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Ascentage Pharma Group International (AAPGV) - P/S Multiple
